Xingli Zhao

Nanchang University — China

Medicine · Health Sciences

18h-index1.2kcitations171works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(52), Cancer Immunotherapy and Biomarkers(22), Chronic Myeloid Leukemia Treatments(22), Acute Lymphoblastic Leukemia research(16), Histone Deacetylase Inhibitors Research(14)

Publications169 total

Personality, Stereotypy, and Responses to Crate Entry in Captive Giant Pandas
Animals·2025Open Access
Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies
Blood·2025
Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study
Blood·2025Open Access
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial
Blood·2025Open Access
7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia
Blood·2025
BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study
Blood·2025Open Access
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion
Blood·2025Open Access
Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial
Blood·2025Open Access
7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations
Blood·2025
Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma
Blood·2025Open Access
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study
British Journal of Haematology·2025
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Efbemalenograstim Alfa (F-627), a Novel Long-Acting rhG-CSF, in Healthy Chinese Participants: An Open-Label, Single-Center Phase I Study
Clinical Drug Investigation·2025
Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment
Journal of Medicinal Chemistry·2025· 2 cited
A Correlation of Geriatric Nutritional Risk Index With the Progression of Sarcopenia in Patients With Lung Cancer
British Journal of Hospital Medicine·2025· 1 citedOpen Access
RC48-ADC Combined with Radiotherapy and Immunotherapy as Salvage Therapy for Advanced Solid Tumors with HER2 Expression: A Multicenter, Phase II Trial
International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited
A Novel PHyLiC Model Using Dynamic Circulating Biomarkers to Predict Efficacy in Radioimmunotherapy for Advanced Solid Tumors
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Mesenchymal Stem Cell-Derived Mitochondrial Transfer Promotes Tip Cell Phenotype via Glutathione Metabolic Reprogramming in Stroke Mice
ACS Nano·2025· 4 cited
Updated results of a phase 2 study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
Journal of Clinical Oncology·2025
Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.
Journal of Clinical Oncology·2025
Research on Short-Term Power Load Prediction Model Based on Polynomial Fitting
2025· 1 cited
page 1 of 9Next →

Frequent Co-authors

Jianxiang Wang(11), Xiaoyuan Gong(9), Yingchang Mi(9), Bingcheng Liu(8), Hui Wei(7), Chao Du(6), Benfa Gong(6), Ying Wang(6), Dong Lin(6), Chunlin Zhou(6), Fangchao Xue(5), Dayson Moreira(5), Marcin Kortylewski(5), Kaiqi Liu(5), Zhongbao Gao(5), Wenyan Zhao(5), Wen Zeng(5), Piotr Swiderski(4), Zhuoran Zhang(4), Yu Tian(4)